建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。
Focus News
11.14 2022
Phase I clinical trial application for bispecific antibody AP505 submitted to Taiwan FDA.
09.10 2022
Phase I clinical trial application for bispecific antibody AP203 submitted to U.S. FDA
AP Biosciences Announces FDA Clearance for Investigational New Drug (IND) Application for AP203, a Novel Bispecific Cancer Immunotherapy
